foxo4-dri senolytic human trial 2024 2025 The costs and benefits of senotherapeutics for health Cellular senescence and senolytics: the
Cellular senescence and senolytics: the path to the clinic Nature Medicine Rubedo Life Sciences has reached an exciting milestone with the launch of its Phase 1 clinical trial for RLS1496, a firstinclass GPX4 modulator designed to selectively target pathologic senescent cells, a key FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect FOXO4 DRI 10mg vial Description RCpeptides Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $6.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20



